Skip to content

Contact Us: 1-518-583-0095    Follow Criterium on LinkedIn    We’re Hiring… Join Our Team!

Request a Proposal
Criterium
  • Home
  • Services
    • Clinical Trial Services
    • Client Services
    • IVR/IWR & ePRO
    • Criterium Technology
    • Retrospective Studies
    • CORE Science Solutions
  • Oncology Consortia
    • Breast Cancer (ABRCC)
    • GI Cancer (AGICC)
    • Myeloma (AMyC)
    • Thoracic Oncology (ATOMIC)
    • Genitourinary Cancer (AURIC)
  • Therapeutic Areas
  • Resources
    • Case Studies
    • Publications & Abstracts
    • Videos & Podcasts
    • Whitepapers
    • Newsletter Archives
    • About Clinical Trials
  • News & Blog
  • About Us
    • The Criterium Edge
    • Executive Team
    • History
    • International Reach
  • Contact Us
    • Site Registration
    • Careers
  • Home
  • Services
    • Clinical Trial Services
    • Client Services
    • IVR/IWR & ePRO
    • Criterium Technology
    • Retrospective Studies
    • CORE Science Solutions
  • Oncology Consortia
    • Breast Cancer (ABRCC)
    • GI Cancer (AGICC)
    • Myeloma (AMyC)
    • Thoracic Oncology (ATOMIC)
    • Genitourinary Cancer (AURIC)
  • Therapeutic Areas
  • Resources
    • Case Studies
    • Publications & Abstracts
    • Videos & Podcasts
    • Whitepapers
    • Newsletter Archives
    • About Clinical Trials
  • News & Blog
  • About Us
    • The Criterium Edge
    • Executive Team
    • History
    • International Reach
  • Contact Us
    • Site Registration
    • Careers
×

Tag: consortia

  1. Home
  2. Tag Archives: consortia

Healio Honors in Medical Oncology: D. Ross Camidge, MD, PhD, University of Colorado

D. Ross Camidge, MD, PhD

Learn more about D. Ross Camidge, MD, PhD, University of Colorado, Director of the Academic Thoracic Oncology Medical Investigators’ Consortium (ATOMIC), who was honored by a colleague for the 2023 Healio Honors in Medical Oncology.

Continue reading
consortia

Interview with Dr. Matthew Milowsky of the Academic Urology Research Investigators Consortium (AURIC)

Dr. Milowsky

Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab.

Continue reading
consortia

CU Cancer Center’s D. Ross Camidge, MD, PhD, Honored by the International Association for the Study of Lung Cancer(IASLC)

CU Cancer Center’s D. Ross Camidge, MD, PhD, Honored by the International Association for the Study of Lung Cancer

Dr. Camidge received the organization’s Daniel C. Ihde Lectureship Award for Medical Oncology.

Continue reading
consortia

Dr. D. Ross Camidge and Dr. Peter Kabos Win University of Colorado Recognition Awards

Peter Kabos, MD, Associate Professor, Division of Medical Oncology (L) and D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology (R)

Dr. Peter Kabos, MD, Associate Professor, Division of Medical Oncology and Dr. D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology were recently honored by the University of Colorado’s Division of Medical Oncology.

Continue reading
consortia

ATOMIC Investigators Meeting – Investigators Meet at IASLC For the First Time Since Covid

ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.

Continue reading
consortia

AGICC Investigator’s Meeting – Investigators Meet at ASCO GI For the First Time Since Covid

AGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies. 

Continue reading
consortia

AURIC Investigator’s Meeting – Successful First Meeting of Newly Formed Group

The Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.

Continue reading
consortia
  • Previous
  • 1
  • 2
  • 3

Recent Articles

Academic GI Cancer Consortium Multicenter Phase II Trial Published in The Oncologist

The Latest Research in Blood Disorders

Oncology News from Leading Researchers – September 2026

2026 Skin Cancer Facts and Statistics

Oncology News from Leading Researchers – July 2026

Get to Know Us!

Request a Proposal

Contact Us

Criterium Headquarters
358 Broadway, Suite 201
Saratoga Springs, NY 12866

Phone: 1-518-583-0095
Fax: 1-518-583-0394

Follow Criterium on LinkedInFollow Us on LinkedIn

About Us

The Criterium Edge

Executive Team

History

International Reach

Careers

Services

Clinical Trial Services

Client Services

IVR/IWR & ePRO

Criterium Technology

CORE Science Solutions

Our Experience

Oncology Consortia

Therapeutic Areas

Privacy Policy    |   Sitemap   |   Clinical Site Registration   |   CRA Registration

© COPYRIGHT CRITERIUM, INC. 2026. ALL RIGHTS RESERVED.

Manage Cookie Consent
We use cookies to optimize our website.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View Preferences
{title} {title} {title}
Manage Cookie Consent
We use cookies to optimize our website.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View Preferences
{title} {title} {title}